{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Lymphoid+Leukemia%2C+Disease+%28disorder%29&page=67", "query": { "condition": "Acute Lymphoid Leukemia, Disease (disorder)", "page": 67 }, "page_size": 10 }, "pagination": { "page": 67, "page_size": 10, "total_count": 1688, "total_pages": 169, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Lymphoid+Leukemia%2C+Disease+%28disorder%29&page=68&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Lymphoid+Leukemia%2C+Disease+%28disorder%29&page=66&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T13:32:40.013Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00698685", "title": "Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Hodgkin's Disease", "Hematologic Neoplasms", "Multiple Myeloma", "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pentostatin", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2006-01-23", "completion_date": "2011-04-26", "has_results": true, "last_update_posted_date": "2017-03-31", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 2, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698685" }, { "nct_id": "NCT00036946", "title": "VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "25 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036946" }, { "nct_id": "NCT03779854", "title": "Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Undifferentiated Leukemia", "Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Blasts Under 25 Percent of Bone Marrow Nucleated Cells", "Blasts Under 5 Percent of Bone Marrow Nucleated Cells", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome With Excess Blasts-1", "Myelodysplastic Syndrome/Acute Myeloid Leukemia", "Burkitt Leukemia", "Chronic Monocytic Leukemia", "Lymphoblastic Lymphoma", "Mast Cell Leukemia", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "26 Years", "sex": "ALL", "summary": "6 Months to 26 Years" }, "enrollment_count": 45, "start_date": "2019-08-29", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 9, "location_summary": "Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03779854" }, { "nct_id": "NCT00251368", "title": "Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myelocytic, Acute", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "9-Aminocamptothecin (9-AC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "1995-01", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2011-03-10", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251368" }, { "nct_id": "NCT02553460", "title": "Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "ITMHA", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Asparaginase Erwinia Chrysanthemi", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "365 Days", "sex": "ALL", "summary": "Up to 365 Days" }, "enrollment_count": 50, "start_date": "2016-01-29", "completion_date": "2031-10", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553460" }, { "nct_id": "NCT00304018", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 5, "start_date": "2002-10", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-08-14", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304018" }, { "nct_id": "NCT02877082", "title": "Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma", "Graft Versus Host Disease", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Thymoglobulin", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2016-09", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02877082" }, { "nct_id": "NCT00070382", "title": "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070382" }, { "nct_id": "NCT01076270", "title": "Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2010-06", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076270" }, { "nct_id": "NCT00003870", "title": "Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Years to 55 Years" }, "enrollment_count": 40, "start_date": "1999-02", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-31T13:32:40.013Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003870" } ] }